Wenjuan Liu

Wenjuan Liu


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
MSMing-Fen Song
Ming-Fen Song
LCLi-Qiong Chen
Li-Qiong Chen
QSQiong-Yan Shao
Qiong-Yan Shao
LHLinlin Hu
Linlin Hu
WLWenjuan Liu
Wenjuan Liu
YZYonghua Zhang
Yonghua Zhang
Background. Chronic insomnia is a major public health problem, but there are limited effective therapies. Jiawei Suanzaoren Decoction (JW‐SZRD) has been used as an alternative option for treating insomnia. This study aimed to investigate the long‐term efficacy and safety of JW‐SZRD in combination with lorazepam for chronic insomnia. Methods. A total of 207 participants were analyzed in this study. The treatment group (TG) received JW‐SZRD and lorazepam orally, and the control group (CG) received lorazepam alone. The Insomnia Severity Index (ISI), the Self‐Rating Depression Scale (SDS), the Self‐Rating Anxiety Scale (SAS), and the Somatic Self‐rating Scale (SSS) were evaluated at baseline, weeks 4, 8, and 12. The MOS 36‐item Short Form Health Survey (SF‐36) was assessed at baseline and week 12. Adverse effects (AEs) were evaluated by the Treatment Emergent Symptom Scale (TESS). Results. Both TG and CG showed obvious improvements in the sleep onset latency (SOL) (P = 0.001 and 0.005) and total sleep time (TST) (P = 0.0001 and 0.001). However, TG was more effective than CG at weeks 8 (P = 0.02 for SOL, P = 0.008 for TST) and 12 (P = 0.03 for SOL, P = 0.04 for TST), especially in shortening SOL (Cohen’s d = 1.28). The ISI reduction rate in TG was higher than that in CG at weeks 4, 8, and 12 (P = 0.008, 0.001 and 0.001). After treatment, TG had lower SAS scores (P = 0.0001, 0.007), less somatic symptoms (P < 0.05 or 0.01), higher SF‐36 scores (P < 0.05 or 0.01), better compliance (P = 0.0001), and less adverse effects (P < 0.05 or 0.01) than those in CG. Conclusion. The combination of JW‐SZRD with lorazepam can significantly improve sleep quality with fewer AEs. It is an effective treatment and superior to lorazepam alone for chronic insomnia.

1 January 2017 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
MSMing-Fen Song
Ming-Fen Song
LHLinlin Hu
Linlin Hu
WLWenjuan Liu
Wenjuan Liu
YLYi Liu
Yi Liu
XTXiao-Yun Tao
Xiao-Yun Tao
YZYonghua Zhang
Yonghua Zhang
Background. Paroxetine does not show satisfactory therapeutic effect for generalized anxiety disorder (GAD) patients for the first 2–4 weeks of medication. Diazepam is always concurrently used although it has some shortcomings such as physical dependence and withdrawal reactions. In this study, we aimed to identify whether modified Suanzaorentang (MSZRT), a combined Chinese formula including Suanzaorentang (SZRT) and Zhizichitang (ZZCT), could control the anxiety of GAD for the first 4 weeks of paroxetine medication. Methods. 156 GAD patients were randomized to the treatment of paroxetine, paroxetine‐diazepam, or paroxetine‐MSZRT for 4 weeks. Hamilton Anxiety Scale (HAMA) Test and Self‐Rating Anxiety Scale (SAS) Test were determined each week as the evaluation of clinical efficacy. Adverse events (AEs) were also closely observed by performing the Treatment Emergent Symptom Scale (TESS) Test. Results. Both paroxetine‐MSZRT and paroxetine‐diazepam decreased more HAMA and SAS total scores than paroxetine from weeks 1 to 3. Paroxetine‐MSZRT as well as paroxetine‐diazepam had an obviously higher onset rate than paroxetine in each week. After 4 weeks’ treatment, the overall effectiveness rate in the paroxetine‐MSZRT group (90.00%) was obviously higher than those of the paroxetine group (74.42%) but did not significantly differ from the paroxetine‐diazepam group (93.88%). Conclusion. MSZRT had the treatment effect for GAD when paroxetine was used for the first 4 weeks.

18 March 2026 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
YWYou-Dan Wei
You-Dan Wei
LRLi-Shan Ren
Li-Shan Ren
JZJun-Hang Zhang
Jun-Hang Zhang
MCMing-Jian Cai
Ming-Jian Cai
CMCai-E Ma
Cai-E Ma
WLWenjuan Liu
Wenjuan Liu
This study aims to explore the associations between napping and subjective sleep quality and daytime functioning in insomnia patients, providing a valuable

30 June 2026 in ALPHA PSYCHIATRY
Verified
Journal Article
Open access
PDF file
LRLishan Ren
Lishan Ren
YWYoudan Wei
Youdan Wei
MCMingjian Cai
Mingjian Cai
MSMingfen Song
Mingfen Song
KZKaiyuan Zhang
Kaiyuan Zhang
WLWenjuan Liu
Wenjuan Liu
Background: Differentiating between bipolar depression (BD) and unipolar depression (UD) presents a significant clinical challenge. Identifying the potential clinical features that distinguish between these two disorders is essential for optimizing personalized management strategies for individuals with depression. In this study, we employed machine learning to develop a classification model to distinguish between BD and UD based on demographic and clinical features. Methods: Patients with either BD or UD were included in this study. Three machine learning classifiers, including logistic regression (LR), random forest (RF), and support vector machine (SVM) were developed and compared using a dual evaluation strategy: (i) nested stratified cross-validation (5-fold outer, 3-fold inner) for unbiased model comparison; and (ii) an independent stratified hold-out split for final validation. In the latter phase, hyperparameters were optimized on the training set via grid search, with performance reported on the test set using bootstrapped 95% confidence intervals. Shapley Additive Explanations (SHAP) analysis was applied to the optimal model to elucidate feature importance. Results: A total of 449 patients (239 UD and 210 BD) were included. All three models achieved a consistent area under the receiver operating characteristic curve (ROC-AUC) of approximately 0.78, indicating moderate discriminative capacity, with the RF model demonstrating a more balanced error distribution. The top six predictive features were: family history, age, sleep disturbance (Patient Health Questionnaire-9 [PHQ9] item 3), fatigue (PHQ9 item 4), use of sleep medication (Pittsburgh Sleep Quality Index [PSQI] item 6), and suicidal ideation (PHQ9 item 9). The SHAP analysis suggested that younger age, “uncertain/unknown” family history, and the use of sleep medication tended to push predictions toward BD, whereas suicidal ideation, sleep disturbance, and fatigue tended to push predictions toward UD. Conclusions: Our machine learning approach identified key predictors—including age, family history, and sleep-related symptoms—to differentiate UD from BD in adolescent and young adult patients. Although achieving moderate accuracy, the model may serve as a supportive screening tool to enhance clinical decision-making.

29 April 2026 in BMC Psychiatry
Verified
Journal Article
Open access
LYLili Yang
Lili Yang
PYPan Yan
Pan Yan
YXYou Xu
You Xu
LHLinlin Hu
Linlin Hu
JWJia Wei
Jia Wei
HMHongjing Mao
Hongjing Mao
This study aimed to investigate Item s associated with treatment response to a phone-based, CBT-I-centered digital intervention in patients with depressive disorders, with a primary focus on sleep-related improvement and its association with changes in depressive symptoms. A total of 307 outpatients with depressive disorders were enrolled from a sleep disorders clinic and received a phone-based, CBT-I-centered digital intervention delivered via a mobile application, in addition to routine pharmacotherapy. The intervention primarily targeted sleep disturbances and incorporated CBT techniques and psychoeducation. Participants completed demographic questionnaires and were assessed using the Pittsburgh Sleep Quality Index (PSQI), Patient Health Questionnaire-9(PHQ-9), Patient Health Questionnaire-15 (PHQ-15), and Epworth Sleepiness Scale (ESS).Treatment response was defined as a ≥ 50% reduction in total PHQ-9 score. Item s influencing treatment response at weeks 8 and 12, as well as Item s associated with residual symptoms at week 12, were analyzed. Univariate analyses showed that age and education level were significantly associated with treatment response at both weeks 8 and 12 (P < 0.05), whereas gender was not. Multivariate logistic regression indicated that younger age (< 30 years) and longer disease duration (> 3 years) were independently associated with poorer treatment outcomes at both follow-up points.At week 12, residual symptoms were significantly associated with younger age, longer disease duration, poorer sleep quality (higher PSQI scores), greater somatic symptom burden (PHQ-15), and increased daytime sleepiness (ESS).Multivariate analyses identified younger age, longer disease duration, and family history of depression as independent risk Item s for residual symptoms. This real-world study suggests that a CBT-I-centered digital intervention primarily targeting sleep disturbances may be associated with concurrent improvements in depressive symptoms among patients with depression. Younger patients and those with longer illness duration appear to be at higher risk for poorer outcomes and persistent residual symptoms. ChiCTR2500103629.

7 August 2026 in Medicine
Verified
Journal Article
Open access
QCQiuyu Chen
Qiuyu Chen
JWJiaxin Wang
Jiaxin Wang
HFHanxin Fu
Hanxin Fu
WLWenjuan Liu
Wenjuan Liu
LYLili Yang
Lili Yang
LHLinlin Hu
Linlin Hu
The study aims to assess the mental health burden among Chinese adolescents aged 10 to 19 years via the 2021 Global Burden of Diseases Study (GBD). Data on the disease burden owing to mental health conditions of Chinese adolescents aged 10 to 19 years from 1990 to 2021 were obtained from the GBD 2021. Disability-adjusted life of years, years of life lost (YLLs), years lived with disability (YLDs), and the prevalence rates of mental disorders (MDs), substance use disorders (SUDs) and self-harm were plotted against sociodemographic index from 1990 to 2021. Temporal trends in the disease burden were evaluated using the Joinpoint Regression. The Nordpred model was applied to project the disease burden over the next 25 years. The burdens of MDs, SUDs, and self-harm accounted for 31.3% of total YLDs and 7.1% of total YLLs among Chinese adolescents aged 10 to 19 years in 2021. These conditions contributed 1439 YLDs (average annual percentage change [AAPC] = −0.2, 95% CI: −0.3 to −0.1) and 139 YLLs (AAPC = −5.2, 95% CI: −5.6 to −4.8). Significant increases in YLDs were observed for eating disorders (AAPC = 1.3, 95% CI: 1.2 to 1.4), whereas intellectual disabilities and developmental disorders significantly decreased (AAPC = −1.4, 95% CI: −1.5 to −1.3). Differences were evident across age and sex groups. The burden of SUDs reaches to the lowest point with an sociodemographic index value of 0.68. Among GBD-quantified risk factors, bullying victimization was a major contributor to disability. The burden of MDs and SUDs is projected to continue increasing over the next 25 years. The mental health burden among Chinese adolescents is a leading contributor to disability. Model-based projections suggest increasing future burdens of MDs and SUDs, underscoring the need for regularly updated, age- and sex-specific adolescent mental health policies.